Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TSPO | P30536 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9707452 | 0.93 | ALOX5 (0.86) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL10457535 | 0.91 | ALOX5 (0.82) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL9707292 | 0.89 | ALOX5 (0.81) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL9707284 | 0.86 | ALOX5 (0.75) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL9707248 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1PTGS2MAOBNR4A2 | |
| SCHEMBL9474556 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1PTGS2L3MBTL1NR4A1 | |
| SCHEMBL6418344 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL9474361 | 0.84 | ALOX5 (0.72) | ALOX5PTGS1PTGS2L3MBTL1TSPO | |
| SCHEMBL9707675 | 0.84 | ALOX5 (0.72) | ALOX5PTGS1PTGS2L3MBTL1MAOB | |
| SCHEMBL9707377 | 0.84 | ALOX5 (0.72) | ALOX5PTGS1PTGS2L3MBTL1TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0196184-B1 | ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-16 | — | — | EP | claimed |
| EP-0196674-A2 | Hydroxamates as modulators of arachidonic acid metabolic pathways | USV PHARMACEUTICAL CORPORATION (US) | 1986-10-08 | — | — | EP | claimed |
| EP-0196184-A2 | Aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-10-01 | — | — | EP | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0196184-B1 | ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-16 | — | — | EP | disclosed |
| US-5036157-A | Hydroxamic acid derivatives, lipoxygenase and cyclooxygenase inhibitors, anticoagulants, antiinflammatory agents | BURROUGHS WELLCOME CO. | 1991-07-30 | — | — | US | disclosed |
| US-4977188-A | Hydroamic acid derivatives | BURROUGHS WELLCOME CO. (US) | 1990-12-11 | — | — | US | disclosed |
| WO-1990001929-A1 | NEW MEDICAL USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| US-4792560-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1988-12-20 | — | — | US | disclosed |
| US-4738986-A | CYCLOOXYGENASE, LIDOXYGENASE INHIBITORS | BURROUGHS WELLCOME CO. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0196184-A2 | Aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885PTGS1 76/4885PTGS2 99/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885PTGS1 76/4885PTGS2 99/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885PTGS1 593/4885PTGS2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.